Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Guilford Pharmaceuticals Inc.

(GLFD)

Franklin Berger of Josephthal, Lyon & Ross began coverage with a "buy" and a one year price target of $8.50. He

Read the full 257 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE